A Trial Investigating Lu AF28996 in Healthy Adult Participants
Completed · Phase 1 · NCT06277609
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $704,090
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- H. Lundbeck A/S
- Tested
- Lu AF28996 (drug), Acetylsalicylic Acid (drug), Mefenamic Acid (drug), Amoxicillin/clavulanic acid (drug)
- Dates
- Started 2024-02-27; completion 2024-05-19
- Results posted
- Not yet
The purpose of this study is to investigate repeated doses of Lu AF28996 in healthy participants and co-administered with two other compounds, and in a separate cohort following co-administration with antibiotics, to see how well the doses are tolerated and what the body does to the drug after administering it.
From ClinicalTrials.gov, last updated 2024-06-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
H. Lundbeck A S reported $704,090 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
- Christine L. Hale, M.D. Emergency Medicine · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc - Madison $521,666
- Fortrea Clinical Research Unit - Dallas $182,424
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.